Zephyrus Biosciences, a UC Berkeley spinout developing next-gen western blotting, just got absorbed by Bio-Techne Corporation for an undisclosed sum.
Zephyrus, a QB3 and Stanford StartX alum, has been building protein analysis tools for research. Specifically, the Z1 System allows western blotting to occur at the individual cell level. It lets researchers analyze heterogenous cell samples – making cellular analysis more efficient.
The company was spun out of researcher Amy Herr’s lab at UC Berkeley in 2013; that year, she published an outline of the company’s approach in Nature Methods.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
“The acquisition of Zephyrus demonstrates our continued interest in western blotting, a vital technique in protein identification and characterization,” Bio-Techne CEO Charles Kummeth said in a statement.